9171 Towne Centre Drive
San Diego, CA 92122
Neothetics, Inc., a clinical-stage specialty pharmaceutical company, engages in developing therapeutics for the aesthetic market. Its lead product candidate includes LIPO-202, an injectable formulation of salmeterol xinafoate that has completed Phase II development for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The company is also developing LIPO-102, which is an injectable form of salmeterol xinafoate and fluticasone propionate for the treatment of the orphan indication of symptomatic exophthalmos or protrusion of the eye from the orbit associated with thyroid-related eye diseases. The company was formerly known as Lipothera, Inc. and changed its name to Neothetics, Inc. in August 2014. Neothetics, Inc. was founded in 2007 and is headquartered in San Diego, California.